SAR302503
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematopoietic Neoplasm
Conditions
Hematopoietic Neoplasm
Trial Timeline
Oct 1, 2011 → May 1, 2014
NCT ID
NCT01420783About SAR302503
SAR302503 is a phase 2 stage product being developed by Bristol Myers Squibb for Hematopoietic Neoplasm. The current trial status is completed. This product is registered under clinical trial identifier NCT01420783. Target conditions include Hematopoietic Neoplasm.
What happened to similar drugs?
1 of 3 similar drugs in Hematopoietic Neoplasm were approved
Approved (1) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01762462 | Phase 1 | Completed |
| NCT01692366 | Phase 2 | Completed |
| NCT01763190 | Phase 1 | Completed |
| NCT01523171 | Phase 2 | Completed |
| NCT01420783 | Phase 2 | Completed |
| NCT01420770 | Phase 2 | Completed |
Competing Products
20 competing products in Hematopoietic Neoplasm